Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 2
2018 2
2019 3
2020 3
2021 3
2022 3
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: . Clear all
Page 1
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 - VERITAS study.
Mauro FR, Starza ID, Messina M, Reda G, Trentin L, Coscia M, Sportoletti P, Orsucci L, Arena V, Casaluci GM, Marasca R, Murru R, Laurenti L, Ilariucci F, Stelitano C, Mannina D, Massaia M, Rigolin GM, Scarfò L, Marchetti M, Levato L, Tani M, Arcari A, Musuraca G, Deodato M, Galieni P, Patrizi VB, Gottardi D, Liberati AM, Giordano A, Molinari MC, Pietrasanta D, Mattiello V, Visentin A, Vitale C, Albano F, Neri A, De Novi LA, De Propris MS, Nanni M, Del Giudice I, Guarini A, Fazi P, Vignetti M, Piciocchi A, Cuneo A, Foà R. Mauro FR, et al. Among authors: mattiello v. Haematologica. 2023 Aug 1;108(8):2091-2100. doi: 10.3324/haematol.2022.282116. Haematologica. 2023. PMID: 36632738 Free PMC article. Clinical Trial.
Lymphadenopathy as a predictor of progression during venetoclax treatment in chronic lymphocytic leukemia. A campus chronic lymphocytic leukemia study.
Autore F, Innocenti I, Reda G, Visentin A, Vitale C, Piciocchi A, Fresa A, Leone MMA, Farina L, Quaresmini G, Baratè C, Giordano A, Ferrari A, Angeletti I, De Paolis MR, Malerba L, Chiurazzi F, Loseto G, Catania G, Sportoletti P, Scortechini I, Moia R, Gentile M, Rigolin GM, Mattiello V, Gattei V, Coscia M, Trentin L, Foà R, Cuneo A, Laurenti L. Autore F, et al. Among authors: mattiello v. Hematol Oncol. 2023 Dec;41(5):877-883. doi: 10.1002/hon.3199. Epub 2023 Jul 1. Hematol Oncol. 2023. PMID: 37392141
Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi.
Zamprogna G, Frustaci AM, Travi G, Borella C, Reda G, Motta M, Deodato M, Bossi E, Mattiello V, Ferrari MB, Cotilli G, Gambacorti-Passerini C, Cairoli R, Puoti M, Tedeschi A. Zamprogna G, et al. Among authors: mattiello v. Hemasphere. 2023 May 4;7(5):e880. doi: 10.1097/HS9.0000000000000880. eCollection 2023 May. Hemasphere. 2023. PMID: 37153871 Free PMC article. No abstract available.
Ibrutinib in patients over 80 years old with CLL: a multicenter Italian cohort.
Reda G, Mattiello V, Frustaci AM, Visentin A, Mauro FR, Innocenti I, Gentile M, Giannarelli D, Noto A, Cassin R, Neri A, Laurenti L, Tedeschi A. Reda G, et al. Among authors: mattiello v. Blood Adv. 2023 Feb 28;7(4):525-528. doi: 10.1182/bloodadvances.2022007619. Blood Adv. 2023. PMID: 35930765 Free PMC article. No abstract available.
Cohort-based association study of germline genetic variants with acute and chronic health complications of childhood cancer and its treatment: Genetic Risks for Childhood Cancer Complications Switzerland (GECCOS) study protocol.
Waespe N, Strebel S, Nava T, Uppugunduri CRS, Marino D, Mattiello V, Otth M, Gumy-Pause F, Von Bueren AO, Baleydier F, Mader L, Spoerri A, Kuehni CE, Ansari M. Waespe N, et al. Among authors: mattiello v. BMJ Open. 2022 Jan 24;12(1):e052131. doi: 10.1136/bmjopen-2021-052131. BMJ Open. 2022. PMID: 35074812 Free PMC article.
23 results